News & Updates
Filter by Specialty:
IBD therapies do not increase risk of contracting COVID-19 after immunization
Using biologic/small molecules*, systemic steroids, or other agents** to treat patients with inflammatory bowel disease (IBD) does not increase the rate of SARS-CoV-2 infection at 3 and 6 months post-immunization, according to a study presented at AIBD 2021.
IBD therapies do not increase risk of contracting COVID-19 after immunization
18 Dec 2021
Early vedolizumab treatment uncommon in IBD
In patients with inflammatory bowel disease (IBD), the likelihood of early treatment with vedolizumab is low, a finding that diverts from guideline recommendations, according to a real-world study presented at AIBD 2021.
Early vedolizumab treatment uncommon in IBD
17 Dec 2021
Remote management during chemotherapy fails to reduce ED visits, hospitalization
A remote, proactive, and telephone-based management of toxicities in outpatients during adjuvant or neoadjuvant chemotherapy for early-stage breast cancer does not lead to fewer visits to the emergency department (ED) or hospital admissions, a study has shown.
Remote management during chemotherapy fails to reduce ED visits, hospitalization
17 Dec 2021
Apixaban outdoes rivaroxaban at preventing VTE, bleeding in adults
Patients with venous thromboembolism (VTE) who are new users of apixaban are less likely to experience recurrent VTE and bleeding than new users of rivaroxaban, a study has shown.
Apixaban outdoes rivaroxaban at preventing VTE, bleeding in adults
17 Dec 2021
No benefit from adding interferon beta-1a to remdesivir in COVID-19
Adding interferon beta-1a to remdesivir did not hasten time to recovery among adults hospitalized with COVID-19, according to results of the phase III ACTT*-3 trial.
